Atrial fibrillation (AF) affects approximately one-third of individuals aged 80 years and over and is associated with a wide range of adverse clinical outcomes, including heart failure (HF), ischemic stroke and systemic embolic events, recurrent hospitalizations, cognitive impairment and dementia, poor quality of life, and death [1]. The cornerstones of AF prevention and treatment include managing comorbidity and risk factors, preventing stroke and thromboembolism, and optimizing symptoms through rate and rhythm control with dynamic and periodic reassessments [1].
